Study to Test if TEV-48574 is Effective in Relieving Asthma

Study Title
A Study to Test if TEV-48574 is Effective in Relieving Asthma
Teva Identifier
TV48574-AS-20031 | 2020-001927-15
ClinicalTrials.gov Identifier
NCT04545385
Study Status
Terminated
Trial Condition(s)
Asthma
Interventions
Drug: TEV-48574 | Drug: Placebo
EudraCT Number
2020-001927-15

Study Description

The primary objective of the study is to evaluate the effect of TEV-48574 compared with placebo on loss of asthma control (LoAC) in adult patients with T2-low and non-T2 severe asthma uncontrolled on inhaled corticosteroids plus long-acting beta-agonists (ICS+LABA).

The secondary efficacy objective is to evaluate the effect of TEV-48574 compared with placebo on a range of clinical measures of asthma control.

The duration of patient participation in the study is planned to be up to approximately 30 weeks.

Print

Participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age group
Adult, Older Adult
Age Range
18 Years and older
Trial Duration
August 25, 2020 - January 17, 2022
Phase
Phase 2

Additional info

Study Type

Interventional